

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

**INSIDE INFORMATION
FURTHER UPDATES IN RELATION TO
CO-DEVELOPMENT AGREEMENT –
U.S. FDA SECOND PHASE 3 CLINICAL TRIAL (“VISTA-2”)
IN DRY EYE DISEASE**

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 16 July 2018 and 23 August 2019 (the “**2019 Announcement**”) in relation to the Co-Development Agreement entered into by Essex Bio-Investment (a wholly-owned subsidiary of the Company) with Mitotech and Russia Mitotech for the Phase 3 Clinical Trial of an ophthalmic solution containing SkQ1 for dry eye disease and the announcement of the Company dated 12 December 2019 in relation to certain updates thereon. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the 2019 Announcement.

The Board is pleased to announce that, as informed by Mitotech, the topline data of VISTA-2 will be released and presented on 24 February 2021 after trading hours, and an announcement will be made by the Company accordingly.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 22 February 2021

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.